Biopharma Daily Stock Updates - 01/14/21

$XBI $153.43 (+3.27%) 📈

COVID:

$VRNA (+4.64%) - Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

https://www.veronapharma.com/media/verona-pharma-completes-enrollment-pilot-study-pmdi-ensifentrine

PIPELINE:

$ACRX (-6.53%) - AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements

https://ir.acelrx.com/news-releases/news-release-details/acelrx-announces-year-end-2020-metrics-and-review-2020

$LXRX (+105.36%) - Phase 3 clinical studies can support a new drug application (NDA) submission

http://www.lexpharma.com/media-center/news/773-lexicon-pharmaceuticals-provides-regulatory-update-on-sotagliflozin-in-heart-failure

$ALKS (+0.82%) - NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine

https://investor.alkermes.com/news-releases/news-release-details/nida-funded-study-evaluating-extended-release-injectable

$BCYC (+28.46%) - Bicycle Therapeutics Announces Pipeline Progress Update

https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-pipeline-progress-update-0

$ETON (+5.68%) - Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-acquisition-canadian-rights

$MIRM (-5.24%) - Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis

https://mirumpharma.gcs-web.com/news-releases/news-release-details/mirum-pharmaceuticals-announces-first-patient-enrolled-phase-2b

$NK (+20.37%) - NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-immunitybio-announce-positive-interim-data-survival?field_nir_news_date_value[min]=
 

$ONCT (+11.59%) - Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program

https://investor.oncternal.com/news-releases/news-release-details/oncternal-therapeutics-inc-confirms-lentigen-technology-inc

$ERYP (+0.27%) - ERYTECH ANNOUNCES FIRST PATIENT ENROLLED IN A PHASE 1 INVESTIGATOR SPONSORED TRIAL OF ERYASPASE IN FIRST-LINE PANCREATIC CANCER

https://investors.erytech.com/news-releases/news-release-details/erytech-announces-first-patient-enrolled-phase-1-investigator

$ORTX (+12.52%) - Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)

https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-otl-200-granted-regenerative

$XENE (+1.83%) - Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021

https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-and

FINANCIAL:

$PRVB (-6.93%) - Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock

http://investors.proventionbio.com/2021-01-13-Provention-Bio-Announces-Pricing-of-100-Million-Public-Offering-of-Common-Stock

$RDHL (-2.38%) - RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering

https://ir.redhillbio.com/news-releases/news-release-details/redhill-biopharma-announces-closing-25-million-bought-deal